Breaking News
December 11, 2017 - MIT researchers discover new way to make bacteria vulnerable to existing antibiotics
December 11, 2017 - Office Workers Don’t Like Being Chained to Their Desks: MedlinePlus Health News
December 11, 2017 - Study reveals how a very low calorie diet can reverse type 2 diabetes
December 11, 2017 - University of Adelaide receives $23.2 million for preterm birth research
December 11, 2017 - Tough Flu Season Ahead: Vaccine May Only Be 10% Effective
December 11, 2017 - Getting Self-Driving Cars on the Road Soon Might Save Lives: MedlinePlus Health News
December 11, 2017 - Enterovirus vaccine prevents virus-induced diabetes in a T1D experimental model
December 11, 2017 - Solar retinopathy or sun damage to the eyes – a case report
December 11, 2017 - Cancer risk with birth control pills emerges again in latest study
December 10, 2017 - Deer Hunters: Put Safety First: MedlinePlus Health News
December 10, 2017 - High blood pressure is redefined as 130, not 140: US guidelines (Update)
December 10, 2017 - Unusual neuroinflammation may underlie cognitive problems in cART-treated HIV patients
December 10, 2017 - Racial differences in parents’ reports of child’s autism symptoms may contribute to delayed diagnosis
December 10, 2017 - Taurine could boost effectiveness of existing multiple sclerosis therapies
December 10, 2017 - The man with a young woman’s heart
December 10, 2017 - Patient bedside remains important component of medical education for students
December 10, 2017 - Nutrition labeling has little impact on sodium consumption
December 10, 2017 - ‘Obesity paradox’ not present among people with new cases of cardiovascular disease
December 10, 2017 - SLU scientists provide promising approach in designing new drugs for DMD
December 10, 2017 - Can PD-1 Inhibitor Help Eradicate HIV?
December 10, 2017 - Checking Prices for Medical Procedures Online? Good Luck: MedlinePlus Health News
December 10, 2017 - Researchers find bacteria tied to esophageal cancer
December 10, 2017 - Boy’s Double Hand Transplant Changed His Brain
December 10, 2017 - Memo to Doctors: Spit Out the Bad News: MedlinePlus Health News
December 10, 2017 - Two years of extended anastrozole therapy proved as effective as five years in clinical trial
December 10, 2017 - Using digital devices before bed may contribute to sleep and nutrition problems in children
December 10, 2017 - Are You Sure That’s What the Doctor Said About Your Leukemia?: MedlinePlus Health News
December 10, 2017 - Low vitamin D levels at birth linked to higher autism risk
December 10, 2017 - Alcohol use in movies influences onset of drinking among 10- to 15-year-olds
December 10, 2017 - For children with ADHD, a brief, school-based program can help dramatically with homework problems, study finds
December 10, 2017 - Surgical Residents Prime Candidates for Stress, Depression, Alcohol Abuse: MedlinePlus Health News
December 10, 2017 - Young athletes commonly develop bone marrow edema in the joints of the lower spine
December 10, 2017 - Coordinated approach in emergency care of heart attacks saves lives
December 10, 2017 - Patients OK With Fewer Opioids After Gallbladder Surgery
December 10, 2017 - Obamacare May Have Helped More Americans Quit Smoking: MedlinePlus Health News
December 10, 2017 - Long-term opioid use does not increase risk of Alzheimer ‘s disease
December 10, 2017 - Brief test can help determine whether drugs, talk therapy work better for treating anxiety
December 10, 2017 - Bioelectronic ‘nose’ can easily sniff foul smells in rotting food
December 10, 2017 - Spontaneous humor can be helpful for cancer patients to deal with distress
December 10, 2017 - Study finds mechanism of resistance to checkpoint inhibitors and way to reverse it
December 10, 2017 - ‘Lesser of two evils’ argument used to defend antipsychotic overuse for dementia
December 10, 2017 - Physical activity in middle age linked to lower incidence of joint symptoms
December 10, 2017 - Optogenetics research sheds new light on social-spatial learning
December 9, 2017 - Guidelines for MRI breast cancer screening not followed in community settings
December 9, 2017 - New first line combination therapy shows promising results in patients with advanced NSCLC
December 9, 2017 - Catheter-Directed Lysis Adds Risk, Not Benefit, for Proximal DVT
December 9, 2017 - Alzheimer’s Cases to Double by 2060: Report: MedlinePlus Health News
December 9, 2017 - New care model closes significant gap in addiction treatment
December 9, 2017 - PARP inhibitor can be new treatment option for patients with metastatic breast cancer, BRCA mutations
December 9, 2017 - Study shows how electrical stimulation in the brain instructs appropriate response
December 9, 2017 - Researchers develop molecular beacon to find hypoxic spots in real time
December 9, 2017 - Many Hospice Workers Lack Their Own End-of-Life Directives: MedlinePlus Health News
December 9, 2017 - New compound stops progressive kidney disease in its tracks
December 9, 2017 - Study: Changes in the brain after childhood limb loss can be reversed
December 9, 2017 - Semaglutide (Ozempic) Approved for Type 2 Diabetes
December 9, 2017 - Study Untangles Disparity in Colon Cancer Survival Rates: MedlinePlus Health News
December 9, 2017 - Lymph node surgery may raise risk of arm morbidity in younger women
December 9, 2017 - Study reveals connection between restless sleep and Parkinson’s disease
December 9, 2017 - Modern non-invasive diagnostics can get clear picture of the heart’s condition
December 9, 2017 - New method helps measure effect of one brain region on another in depression
December 9, 2017 - Mount Sinai study uses adaptive optics to examine retinal eye damage from solar eclipse
December 9, 2017 - Scientists introduce polyproline as effective cryoprotectant for monolayers of cells
December 9, 2017 - Simple molecular test may help predict presence of high-grade pancreatic cancers
December 9, 2017 - High levels of burnout, stress for U.S. surgical residents
December 9, 2017 - Parental lifespan genes could pave way for new therapeutic targets to prolong life
December 9, 2017 - About Half of Americans Get Health Care in ER: MedlinePlus Health News
December 9, 2017 - People with epilepsy may gain from common sleep apnea treatment
December 9, 2017 - Anti-impotence drug found to be ineffective at improving outcomes for IUGR pregnancies
December 9, 2017 - High risk of burnout, depression, and low quality of life found among health care workers
December 9, 2017 - Higher educational attainment associated with lower risk of Alzheimer’s disease
December 9, 2017 - Researchers seek to understand role of novel protein in tumor metastasis
December 9, 2017 - Research brings scientists one step closer to understanding development of ALS
December 9, 2017 - Women and Caregiving: Facts and Figures
December 9, 2017 - Mindfulness meditation found to relieve the stress of waiting for bad news
December 9, 2017 - Common fungus has significant impact on mosquitoes’ ability to transmit dengue virus
December 9, 2017 - Short online program improves ability of teen girls to communicate about safe sex
December 9, 2017 - Researcher discovers enzyme pathway involved in ALS pathogenesis
December 9, 2017 - Fusobacterium may play role in colon cancer growth, study finds
December 9, 2017 - Are Women Naturally Fitter Than Men?
December 9, 2017 - Celecoxib Strikes Out on Cancer Progression
FDA Approves Kaléo’s Auvi-Q (Epinephrine Injection, USP) 0.1 mg Auto-Injector for Life-Threatening Allergic Reactions in Infants and Small Children

FDA Approves Kaléo’s Auvi-Q (Epinephrine Injection, USP) 0.1 mg Auto-Injector for Life-Threatening Allergic Reactions in Infants and Small Children

image_pdfDownload PDFimage_print

Richmond, VA (November 20, 2017) kaléo, a privately-held pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for Auvi-Q (epinephrine injection, USP) 0.1 mg, the first and only epinephrine auto-injector (EAI) specifically designed for the treatment of life-threatening allergic reactions, including anaphylaxis, in infants and small children weighing 16.5 to 33 pounds (7.5 to 15 kilograms) who are at risk for or have a history of serious allergic reactions.

The sNDA for the Auvi-Q 0.1 mg Auto-injector was granted Priority Review by the FDA, an expedited regulatory pathway reserved for products that may provide significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to available therapies.

Auvi-Q is a compact epinephrine auto-injector with industry-first features, including a voice prompt system that guides a user with step-by-step instructions through the delivery process, and a needle that automatically retracts following administration. The new 0.1 mg-dose epinephrine auto-injector has a shorter needle length and lower dose of epinephrine than current FDA approved 0.15 mg and 0.3 mg epinephrine auto-injectors.

Children are increasingly being treated for anaphylaxis. There was a 129.8 percent increase in emergency room visits for anaphylaxis among children four years old and younger between 2005 and 2014.[i] According to a study published in Allergy, Asthma & Clinical Immunology, 43 percent of children weighing 16.5 pounds (7.5 kilograms) to 33 pounds (15 kilograms) treated with a 0.15 mg EAI having a standard 12.7 mm needle length are at risk of having the needle strike the bone, therefore potentially impacting the administration of epinephrine during a life-threatening emergency.[ii] The needle length in Auvi-Q 0.1 mg was specifically designed for use with infants and small children to help mitigate this safety concern.

“Today’s decision by the FDA to approve the Auvi-Q 0.1 mg Auto-injector is exciting for all of us in the life-threatening allergy community who have been working for many years to fulfill this unmet medical need,” said Spencer Williamson, President and CEO of kaléo. “As a company that focuses on patients first, and providing potentially life-saving treatments, we are particularly glad we will be able to help caregivers by providing an EAI that was specifically designed with an appropriate dose and needle length for infants and children (16.5 to 33 pounds) in order to maximize the potential for a safe administration of epinephrine.”

“The approval of Auvi-Q 0.1 mg will help achieve our goal of working to fulfill unmet medical needs,” said Eric S. Edwards, MD, PhD, Vice President of Innovation and Research & Development at kaléo. “We developed the Auvi-Q 0.1 mg EAI to deliver a dose of epinephrine appropriate to infants and small children weighing 16.5 – 33 pounds, with a shorter needle length to help mitigate the risk of striking bone which could potentially cause injury or interfere with the delivery of epinephrine.”

Only Auvi-Q 0.1 mg has a dose and needle length designed specifically for treating anaphylaxis in infants and small children weighing 16.5 – 33 pounds. Auvi-Q 0.1 mg includes the innovative AUVI-Q electronic voice instruction system as well as visual cues to help guide users step-by-step through the administration.

“The approval of an epinephrine auto-injector specifically designed for infants and small children is timely, especially given the recent changes to guidelines recommending that certain high-risk infants, as young as four to six months old, be introduced to peanut-containing foods,” said Eleanor Garrow-Holding[1], President and CEO of the Food Allergy & Anaphylaxis Connection Team (FAACT). “We are pleased that the pediatric allergy healthcare community and parents of infants and small children with life-threatening allergies will have the ability to obtain an FDA-approved epinephrine auto-injector in the event of an allergic emergency. We look forward to the availability of Auvi-Q 0.1 mg.”

“Until now, healthcare practitioners and caregivers to infants and small children have not had an epinephrine auto-injector with an appropriate dose of epinephrine available to them, potentially causing some delay in the administration of epinephrine in a life-threatening allergic emergency,” said Dr. Vivian Hernandez-Trujillo[1], a pediatric allergist, and fellow of the American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; and American Academy of Pediatrics specializing in the management of life-threatening allergies and anaphylaxis. “Having an epinephrine auto-injector with a needle length and dose specifically designed for infants and small children should help alleviate concerns around hitting the bone or injecting too much epinephrine.”

Identical twin brothers, Evan and Eric Edwards, the inventors of Auvi-Q, know what it is like to live with life-threatening allergies, both as patients and parents of food-allergic children. Their goal was to develop an epinephrine auto-injector that contained innovative features, such as a voice instruction system that helps guide patients and caregivers step-by-step through the injection process. Evan and Eric Edwards believe and trust in Auvi-Q, not only for themselves, but also for their children and other families who may have to depend on it to administer epinephrine during an allergic emergency.

The Auvi-Q 0.1 mg Auto-injector is projected to be available for patients in the first half of 2018.

About Anaphylaxis

Anaphylaxis (pronounced ana-fuh-lak-sis) is a serious allergic reaction that happens quickly and may cause death. Anaphylaxis can occur as a result of exposure to allergens including tree nuts, peanuts, milk, eggs, fish, shellfish, soy, wheat, insect bites, latex and medication, among other allergens.

About Auvi-Q (0.3 mg, 0.15 mg and 0.1 mg)

Auvi-Q (epinephrine injection, USP) Auto-injector is a prescription medicine used to treat life-threatening allergic reactions, including anaphylaxis, in people who are at risk for or who have a history of serious allergic reactions. Auvi-Q contains epinephrine, a well-established, first-line treatment for severe, life-threatening allergic reactions that occur as a result of exposure to allergens including food such as peanuts, tree nuts, fish, shellfish, dairy, eggs, soy and wheat; insect stings or bites; latex and medication, among other allergens and causes.

Auvi-Q is the only compact epinephrine auto-injector with a voice instruction system that helps guide patients and caregivers step-by-step through the injection process, and a needle that automatically retracts following administration. In anaphylaxis emergencies, it is often individuals without medical training who need to step in and deliver potentially life-saving epinephrine. Auvi-Q was designed through careful analysis of the situations where epinephrine auto-injectors are used and with significant input from the allergy community that relies on it incorporating Human Factors Engineering (HFE). HFE is about designing products or systems that are easy to operate and, most importantly, support correct use, with the goal to remove the potential for error. For more information about Auvi-Q (0.3 mg, 0.15 mg and 0.1 mg) visit www.auvi-q.com.

About kaléo (kuh-LAY-oh)

Kaléo is a pharmaceutical company dedicated to building innovative solutions for serious and life-threatening medical conditions. Our mission is to provide innovative solutions that empower patients to confidently take control of their medical conditions. We believe patients and caregivers are the experts on how their medical condition impacts their lives and are an integral part of our product development process. Kaléo is a privately-held company headquartered in Richmond, Virginia. For more information, visit www.kaleopharma.com.

[1] Dr. Vivian Hernandez Trujillo and Eleanor Garrow-Holding are paid consultants of kaleo, Inc. and other private companies.
[i] Motosue M., et al. J Allergy Clin Immunol Pract. 2017;5:171-175.
[ii] Kim H., et al. Ann Allergy Asthma Immunol. 2017 Jun;118(6):719-725.

Source: kaléo

Posted: November 2017

Related Articles:

Auvi-Q (epinephrine) FDA Approval History

Tagged with:

About author

Related Articles